



Rheumatology Research Workshop, April 27-28, 2023

Now accepting applications! Deadline to apply is Wednesday, February 22, 12:00 Noon ET.

The ACR is now accepting applications for the 2023 Rheumatology Research Workshop. This two-day, in-person only workshop will be held April 27-28, 2023. The workshop will include scientific lectures, oral abstract presentations, and opportunities for early career investigators to interact with senior investigators. Sessions will focus on how to communicate your research with various audiences, including colleagues, lay press, and funders.

Target Audience

This meeting is designed for:

- A medical student or resident enrolled in an ACGME-accredited pediatric, medicine or combined medicine/pediatric residency program who is interested in rheumatology
- A fellow-in-training at an ACGME-accredited training program that will lead to eligibility to take the ABIM examination in rheumatology or the ABP examination in pediatric rheumatology
- A faculty member within six years of completing their fellowship training program (those who completed their fellowship after May 2017)

Abstract Submission

Applicants must submit an abstract to complete their application. Preliminary findings or proposals for fellowship research projects are encouraged. Accepted applicants will receive feedback on their abstracts or proposals from the ACR's Early Career Investigator Subcommittee. Additional abstract details are included on page 2 of this application.

Applicants must be ACR/ARP members for their application to be reviewed. Applicants will be notified of the status of their application by late March.

The deadline to complete this application is Wednesday, February 22, 12:00 Noon ET.

For questions regarding the Rheumatology Research Workshop, send an email to Latonya Trower at ltrower@rheumatology.org.

Important Dates

Submission Open	January 11
EXTENDED Submission Deadline	February 22
Notification	Early March
Rheumatology Research Workshop	April 27 – 28

Abstract Guidelines

Abstract Eligibility

- Abstracts detailing study design protocols, research-in-progress, preliminary results are eligible for consideration in addition to completed studies
- Case reports are not considered appropriate and will not be reviewed
- Any work with human or animal subjects reported in submitted abstracts must comply with the guiding principles for experimental procedures found in the [Declaration of Helsinki](#) of the World Medical Association

Abstract Format

The abstract limit is 2,750 characters, excluding authors and affiliations, spacing or disclosures. Abstract title and author(s) do not count toward the 2,750 character limit.

Title

Titles should be brief, clearly indicating the nature of the presentation. When entering your title online, use mixed case (do not use all caps), and do not put a period at the end of the title. Do not enter the title in the body of the abstract.

Example: This Is a Properly Formatted Abstract Title

Authors

You may list no more than 25 individual authors for each abstract. In addition to the 25 authors, an authoring group may be listed to indicate the remaining authors.

Content

Omit all institutional names and geographical references in the body of the abstract.

Organize content as follows:

- Background or Statement of Purpose
- Methods, materials, and analytical procedure used
- Summary of the results in sufficient detail to support conclusion. For abstracts detailing study design abstracts or research-in-progress, anticipated results, or hypotheses to be tested are acceptable
- Conclusions reached. For abstracts detailing study design or research-in-progress, significance and implications are acceptable

Use of Product Names

The non-proprietary (generic/scientific) name can be used in your abstract. The proprietary drug name may appear once in parentheses in the title only. However, if a drug has not received FDA approval,



only the non-proprietary name may be used in the title and abstract. Failure to follow this rule will result in disqualification of your submission.

Abbreviations

Use standard abbreviations. A [list of acronyms](#) for many common rheumatology terms has been developed by an international group of rheumatology journal editors. Place special or unusual abbreviations in parentheses after the first time the full word appears.

Do not abbreviate compounds in the title of the abstract. Use numerals to indicate numbers, except when beginning sentences.

Tables and Graphics

A maximum of two tables or figures is allowed. Tables and graphics must be submitted in .jpg or .gif format.